Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
How does your approach to contouring change when treating pancreatic body/tail lesions vs head tumors in the postop setting?
Answer from: Radiation Oncologist at Academic Institution
For tail lesions, we cover the splenic hilum and for head lesions, we cover the porta.
Sign in or Register to read more
11693
Related Questions
Would you consider proton therapy as part of TNT for rectal cancer?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
For anal radiation dermatitis, does anyone have experience with 3M Cavilon protectant?
Is it safe to treat the stomach to a definitive dose if the patient has a G-tube/PEG in place?
Would you change treatment approach for rectal cancer with an associated intussusception?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
When treating pancreatic body/tail lesions that result in significant dose spread to the spleen, what is your threshold to offer pneumococcal, hemophilus influenza, and meningococcal vaccines?
When treating a bulky squamous cell carcinoma of the anal canal, do you try to limit the dose to the external anal sphincter to any particular number to reduce the risk of chronic fecal incontinence?
Would you dose escalate neoadjuvant radiotherapy for T3 and/or N+ rectal cancer in patients who are unwilling or unable to get chemotherapy?